Skip to content

Clinical study to evaluate the efficacy of Chandrashakaladi Vati and Arka Taila in Dry Eczema.

A randomized controlled clinical study to evaluate the efficacy of Chandrashakaladi Vati and Arka Taila in Vicharchika with special reference to Dry Eczema.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/12/060780
Enrollment
140
Registered
2023-12-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L209- Atopic dermatitis, unspecified

Interventions

None listed

Sponsors

Dr Sandhya Suresh Mane
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient diagnosed as vicharchika on the basis of classical lakshans like Kandu ( Itching), Pidika ( Eruption ) , Vaivarnya ( Discolouration ) , Daha ( Burning sensation ), Rookshata ( Dryness ) and Raji ( Thickning of skin )

Exclusion criteria

Exclusion criteria: Age from the group having below 16 and above 70 years. Pregnant and lactating mothers. Patients having Systemic illness like Diabetes Mellitus, Coronary Heart Disease , Renal Disease , HIV, Venereal disease, TB and other bleeding disorders. Patients having Acute Complications like Acute Infective Hepatitis or Alcoholic Hepatitis. Patients having disorders like Carcinoma anywhere in the body. The patch which is infected and having pus collection, secretions.

Design outcomes

Primary

MeasureTime frame
Efficacy of Chandrashakaladi vati and Arka taila in vicharchikaTimepoint: 8 weeks

Secondary

MeasureTime frame
Adverse reactions if any after administration of Chandrashakaladi vati & Arka tailaTimepoint: 8weeks

Countries

India

Contacts

Public ContactDr Sandhya Suresh Mane

Yashwant Ayurvedic College Post Graduate Training and Research Centre

SURYAKIRAN_WAGH@rediffmail.com9822846910

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026